Allergic bronchopulmonary aspergillosis: a US perspective.
OBJECTIVE
The present article is an update of allergic bronchopulmonary aspergillosis. Although a rare condition, allergic bronchopulmonary aspergillosis does affect a number of patients with asthma and cystic fibrosis. Prompt recognition and treatment of the disease is critical to improving patient outcomes.


RESULTS
There is currently much active research being performed in the area of allergic bronchopulmonary aspergillosis. Fascinating insights are being made into the pathophysiology and genetics of the disease. Additionally, research is ongoing on the use of recombinant Aspergillus allergens as an aid to the diagnosis of allergic bronchopulmonary aspergillosis.


CONCLUSIONS
These new insights into the genetics and pathophysiology of allergic bronchopulmonary aspergillosis and the development of these new diagnostic techniques could ultimately lead to improved patient treatment. These areas form an important basis for further research.
Virnig
Christine
C
William S. Middleton VA Hospital, Madison, Wisconsin 53705, USA.
Bush
Robert K
RK
D000908:Antibodies, Fungal / Q000378:metabolism; D000935:Antifungal Agents / Q000627:therapeutic use; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000175:diagnosis / Q000235:genetics* / Q000503:physiopathology* / Q000628:therapy; D001230:Aspergillus / Q000276:immunology; D020022:Genetic Predisposition to Disease; D015802:HLA-DR2 Antigen / Q000235:genetics / Q000276:immunology; D015805:HLA-DR5 Antigen / Q000235:genetics / Q000276:immunology; D006801:Humans; D014481:United States
D000908:Antibodies, Fungal; D000935:Antifungal Agents; D015802:HLA-DR2 Antigen; D015805:HLA-DR5 Antigen